Investor Presentaiton

Clarity summary Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for better diagnostics and treatments in oncology . • Proprietary SAR Technology: a true platform technology that can drive out a range of radiopharmaceuticals Three best-in-class products in clinical development: high accuracy and precision by using the chemically identical product for both diagnosing and treating disease Targeted Copper Theranostics (TCTs) employ copper-64 for diagnosis and imaging and copper-67 for therapy Significant logistical benefits and a scalable, dependable supply Environmental advantages over current isotopes with no reliance on nuclear fuel cycle or long-lived waste products Diagnostic products will be the first to reach the market, generating revenue streams to fund late-stage therapeutic product trials and approvals Highly experienced leadership team 1 ASX code: CU6 2 31 Shares on issue: 257,832,546 Share Price: $0.45/share (at close of 26 May 2022) 4 Market Capitalisation: $116.0M (at close of 26 May 2022) 5 Cash at bank: $95.9M (at 31 Mar 2022) 6 Enterprise value: ~$20.1M (at close of 26 May 2022) • Well funded with $95.9 M in cash (at 31 March 2022 Approximately $5 million R&D refund expected for 2022 CLARITY 2014 MILE 7 Trading range: $0.38-1.71 (52 week) 3

View entire presentation